Total Payments
$2,271
2022 Payments
$175.38
Companies
2
Transactions
9
Medicare Patients
1,338
Medicare Billing
$191,892
Payment Breakdown by Category
Research$2,244 (98.8%)
Food & Beverage$27.04 (1.2%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $2,244 | 8 | 98.8% |
| Food and Beverage | $27.04 | 1 | 1.2% |
Payments by Type
Research
$2,244
8 transactions
General
$27.04
1 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Astellas Pharma Global Development | $2,244 | 8 | $0 (2022) |
| Gilead Sciences Inc | $27.04 | 1 | $0 (2017) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2022 | $175.38 | 1 | Astellas Pharma Global Development ($175.38) |
| 2021 | $428.62 | 3 | Astellas Pharma Global Development ($428.62) |
| 2020 | $1,160 | 3 | Astellas Pharma Global Development ($1,160) |
| 2019 | $480.00 | 1 | Astellas Pharma Global Development ($480.00) |
| 2017 | $27.04 | 1 | Gilead Sciences Inc ($27.04) |
All Payment Transactions
9 individual payment records from CMS Open Payments
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 01/19/2022 | Astellas Pharma Global Development | Cresemba (Drug) | — | In-kind items and services | $175.38 | Research |
| Study: A Non-Interventional Registry Study of Systemic Antifungal Therapy in Adult Subjects with Invasive Mucormycosis or Invasive Aspergillosis Caused by a Non-fumigatus Species • Category: Infectious Diseases | ||||||
| 08/17/2021 | Astellas Pharma Global Development | CRESEMBA (Drug) | — | In-kind items and services | $175.38 | Research |
| Study: A Non-Interventional Registry Study of Systemic Antifungal Therapy in Adult Subjects with Invasive Mucormycosis or Invasive Aspergillosis Caused by a Non-fumigatus Species • Category: HOSPITAL AND TRANSPLANT | ||||||
| 07/22/2021 | Astellas Pharma Global Development | CRESEMBA (Drug) | — | In-kind items and services | $126.62 | Research |
| Study: A Non-Interventional Registry Study of Systemic Antifungal Therapy in Adult Subjects with Invasive Mucormycosis or Invasive Aspergillosis Caused by a Non-fumigatus Species • Category: HOSPITAL AND TRANSPLANT | ||||||
| 06/23/2021 | Astellas Pharma Global Development | CRESEMBA (Drug) | — | In-kind items and services | $126.62 | Research |
| Study: A Non-Interventional Registry Study of Systemic Antifungal Therapy in Adult Subjects with Invasive Mucormycosis or Invasive Aspergillosis Caused by a Non-fumigatus Species • Category: HOSPITAL AND TRANSPLANT | ||||||
| 12/10/2020 | Astellas Pharma Global Development | CRESEMBA (Drug) | — | In-kind items and services | $166.44 | Research |
| Study: A NON-INTERVENTIONAL REGISTRY STUDY OF SYSTEMIC ANTIFUNGAL THERAPY IN ADULT SUBJECTS WITH INVASIVE MUCORMYCOSIS OR INVASIVE ASPERGILLOSIS CAUSED BY A NON-FUMIGATUS SPECIES PROTOCOL FOR PHASE 4 STUDY OF ASP9766 • Category: HOSPITAL AND TRANSPLANT | ||||||
| 04/30/2020 | Astellas Pharma Global Development | CRESEMBA (Drug) | — | In-kind items and services | $675.00 | Research |
| Study: A NON-INTERVENTIONAL REGISTRY STUDY OF SYSTEMIC ANTIFUNGAL THERAPY IN ADULT SUBJECTS WITH INVASIVE MUCORMYCOSIS OR INVASIVE ASPERGILLOSIS CAUSED BY A NON-FUMIGATUS SPECIES PROTOCOL FOR PHASE 4 STUDY OF ASP9766 • Category: HOSPITAL AND TRANSPLANT | ||||||
| 04/18/2020 | Astellas Pharma Global Development | CRESEMBA (Drug) | — | In-kind items and services | $319.00 | Research |
| Study: A NON-INTERVENTIONAL REGISTRY STUDY OF SYSTEMIC ANTIFUNGAL THERAPY IN ADULT SUBJECTS WITH INVASIVE MUCORMYCOSIS OR INVASIVE ASPERGILLOSIS CAUSED BY A NON-FUMIGATUS SPECIES PROTOCOL FOR PHASE 4 STUDY OF ASP9766 • Category: HOSPITAL AND TRANSPLANT | ||||||
| 11/26/2019 | Astellas Pharma Global Development | CRESEMBA (Drug) | — | In-kind items and services | $480.00 | Research |
| Study: A Non-Interventional Registry Study of Systemic Antifungal Therapy in Adult Subjects with Invasive Mucormycosis or Invasive Aspergillosis Caused by a Non-fumigatus Species Protocol for Phase 4 Study of ASP9766 • Category: INFECTIOUS DISEASES | ||||||
| 10/06/2017 | Gilead Sciences Inc | — | Food and Beverage | In-kind items and services | $27.04 | General |
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A NON-INTERVENTIONAL REGISTRY STUDY OF SYSTEMIC ANTIFUNGAL THERAPY IN ADULT SUBJECTS WITH INVASIVE MUCORMYCOSIS OR INVASIVE ASPERGILLOSIS CAUSED BY A NON-FUMIGATUS SPECIES PROTOCOL FOR PHASE 4 STUDY OF ASP9766 | Astellas Pharma Global Development | $1,160 | 3 |
| A Non-Interventional Registry Study of Systemic Antifungal Therapy in Adult Subjects with Invasive Mucormycosis or Invasive Aspergillosis Caused by a Non-fumigatus Species | Astellas Pharma Global Development | $604.00 | 4 |
| A Non-Interventional Registry Study of Systemic Antifungal Therapy in Adult Subjects with Invasive Mucormycosis or Invasive Aspergillosis Caused by a Non-fumigatus Species Protocol for Phase 4 Study of ASP9766 | Astellas Pharma Global Development | $480.00 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 7 | 266 | 395 | $150,340 | $37,526 |
| 2022 | 6 | 284 | 438 | $148,072 | $40,089 |
| 2021 | 9 | 401 | 570 | $216,577 | $58,764 |
| 2020 | 9 | 387 | 570 | $172,581 | $55,513 |
Total Patients
1,338
Total Services
1,973
Medicare Billing
$191,892
Procedure Codes
31
All Medicare Procedures & Services
31 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 54 | 126 | $41,512 | $12,528 | 30.2% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 55 | 60 | $36,634 | $8,596 | 23.5% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 47 | 77 | $16,103 | $5,090 | 31.6% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 44 | 46 | $20,940 | $4,927 | 23.5% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 35 | 51 | $21,335 | $3,883 | 18.2% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2023 | 11 | 12 | $7,302 | $1,289 | 17.6% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2023 | 20 | 23 | $6,514 | $1,212 | 18.6% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 68 | 167 | $43,933 | $13,808 | 31.4% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 68 | 76 | $44,336 | $12,441 | 28.1% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 54 | 80 | $14,880 | $4,744 | 31.9% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 42 | 58 | $24,128 | $4,485 | 18.6% |
| 99222 | Initial hospital inpatient care per day, typically 50 minutes | Facility | 2022 | 30 | 30 | $13,181 | $3,436 | 26.1% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2022 | 22 | 27 | $7,614 | $1,175 | 15.4% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2021 | 101 | 108 | $62,640 | $18,461 | 29.5% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 84 | 188 | $49,068 | $16,555 | 33.7% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 50 | 76 | $31,616 | $6,192 | 19.6% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2021 | 69 | 91 | $16,926 | $5,542 | 32.7% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Facility | 2021 | 22 | 22 | $16,676 | $3,380 | 20.3% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Facility | 2021 | 22 | 27 | $16,070 | $3,294 | 20.5% |
| 99222 | Initial hospital inpatient care, typically 50 minutes per day | Facility | 2021 | 25 | 26 | $11,310 | $2,937 | 26.0% |
| 99204 | New patient outpatient visit, total time 45-59 minutes | Facility | 2021 | 12 | 12 | $6,768 | $1,393 | 20.6% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Facility | 2021 | 16 | 20 | $5,503 | $1,009 | 18.3% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2020 | 105 | 119 | $69,020 | $20,959 | 30.4% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2020 | 81 | 188 | $49,068 | $17,012 | 34.7% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2020 | 72 | 112 | $20,832 | $7,013 | 33.7% |
About Nina Clark
Nina Clark is a Infectious Disease healthcare provider based in Maywood, Illinois. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 08/17/2006. The National Provider Identifier (NPI) number assigned to this provider is 1891809067.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Nina Clark has received a total of $2,271 in payments from pharmaceutical and medical device companies, with $175.38 received in 2022. These payments were reported across 9 transactions from 2 companies. The most common payment nature is "" ($2,244).
As a Medicare-enrolled provider, Clark has provided services to 1,338 Medicare beneficiaries, totaling 1,973 services with total Medicare billing of $191,892. Data is available for 4 years (2020–2023), covering 31 distinct procedure/service records.
Ad
Practice Information
- Specialty Infectious Disease
- Location Maywood, IL
- Active Since 08/17/2006
- Last Updated 05/16/2022
- Taxonomy Code 207RI0200X
- Entity Type Individual
- NPI Number 1891809067
Products in Payments
- CRESEMBA (Drug) $2,069
- Cresemba (Drug) $175.38
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Infectious Disease Doctors in Maywood
Jorge Parada, Md, Mph, MD, MPH
Infectious Disease — Payments: $108,067
Infectious Disease $108,067
Stuart Johnson, Md, MD
Infectious Disease — Payments: $42,944
Infectious Disease $42,944
Dr. Lopa Maharaja, M.d, M.D
Infectious Disease — Payments: $1,437
Infectious Disease $1,437
Dr. Fritzie Albarillo, M.d, M.D
Infectious Disease — Payments: $1,016
Infectious Disease $1,016
Dr. Han Nguyen, M.d, M.D
Infectious Disease — Payments: $989.93
Infectious Disease $989.93
Dr. Eugene French, Md, MD
Infectious Disease — Payments: $250.88
Infectious Disease $250.88